Skip to main content
Top
Published in: Heart and Vessels 12/2022

24-06-2022 | Care | Original Article

Trends in prognosis after hospitalization for acute heart failure in Kurashiki Central hospital 2015–2018: single-center prospective study

Authors: Yuichi Kawase, Kenta Yoshida, Shunsuke Matsushita, Takeshi Tada, Hiromi Yamamoto, Harumi Katoh, Kazushige Kadota

Published in: Heart and Vessels | Issue 12/2022

Login to get access

Abstract

Recently, we have been working on enhancing the effectiveness of treatment for acute heart failure (HF) through team-based care. This study was designed to assess the benefits of this initiative by quantifying the prognostic impact on HF patients receiving treatment at our hospital. We identified 1977 consecutive HF patients (mean age 78.3 ± 11.9 years) being discharged from our hospital between February 2015 and December 2018, divided them by admission year, and tracked changes over time, with 2015 as a reference. The postdischarge clinical outcome measures were defined as a composite of all-cause death or rehospitalization for HF, all-cause death, and rehospitalization for HF. The risk of a composite of all-cause death or rehospitalization for HF was lower in 2017 (adjusted hazard ratio, 0.72; 95% confidence interval: 0.57 to 0.91; p = 0.005) and 2018 (adjusted hazard ratio, 0.78; 95% confidence interval: 0.61 to 0.99; p = 0.045) than in 2015, and that of all-cause death was lower in 2017 (adjusted hazard ratio, 0.72; 95% confidence interval: 0.53 to 0.98; p = 0.04) and 2018 (adjusted hazard ratio, 0.60; 95% confidence interval: 0.43 to 0.85; p = 0.004) than in 2015, but that of rehospitalization for HF was not significantly different through the study period. The mortality rate decreased at the end of the study period, but the rate of rehospitalization for HF did not. The benefits of team-based care were difficult to evaluate by quantification.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yaku H, Ozasa N, Morimoto T, Inuzuka Y, Tamaki Y, Yamamoto E, Yaku H, Ozasa N, Morimoto T, Inuzuka Y, Tamaki Y, Yamamoto E, Yoshikawa Y, Kitai T, Taniguchi R, Iguchi M, Kato M, Takahashi M, Jinnai T, Ikeda T, Nagao K, Kawai T, Komasa A, Nishikawa R, Kawase Y, Morinaga T, Su K, Kawato M, Sasaki K, Toyofuku M, Furukawa Y, Nakagawa Y, Ando K, Kadota K, Shizuta S, Ono K, Sato Y, Kuwahara K, Kato T, Kimura T et al (2018) Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan -observations from the prospective, multicenter Kyoto congestive heart failure (KCHF) registry. Circ J 82(11):2811–2819CrossRef Yaku H, Ozasa N, Morimoto T, Inuzuka Y, Tamaki Y, Yamamoto E, Yaku H, Ozasa N, Morimoto T, Inuzuka Y, Tamaki Y, Yamamoto E, Yoshikawa Y, Kitai T, Taniguchi R, Iguchi M, Kato M, Takahashi M, Jinnai T, Ikeda T, Nagao K, Kawai T, Komasa A, Nishikawa R, Kawase Y, Morinaga T, Su K, Kawato M, Sasaki K, Toyofuku M, Furukawa Y, Nakagawa Y, Ando K, Kadota K, Shizuta S, Ono K, Sato Y, Kuwahara K, Kato T, Kimura T et al (2018) Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan -observations from the prospective, multicenter Kyoto congestive heart failure (KCHF) registry. Circ J 82(11):2811–2819CrossRef
2.
go back to reference Larsen PM, Teerlink JR (2015) Team-based care for patients hospitalized with heart failure. Heart Fail Clin 11:359–370CrossRef Larsen PM, Teerlink JR (2015) Team-based care for patients hospitalized with heart failure. Heart Fail Clin 11:359–370CrossRef
3.
go back to reference McAlister FA, Lawson FME, Teo KK, Armstrong PW (2001) A systematic review of randomized trials of disease management programs in heart failure. Am J Med 110:378–384CrossRef McAlister FA, Lawson FME, Teo KK, Armstrong PW (2001) A systematic review of randomized trials of disease management programs in heart failure. Am J Med 110:378–384CrossRef
4.
go back to reference Kinugasa Y, Kato M, Sugihara S, Yanagihara K, Yamada K, Hirai M, Yamamoto K (2014) Multidisciplinary intensive education in the hospital improves outcomes for hospitalized heart failure patients in a Japanese rural setting. BMC Health Serv Res 14:351CrossRef Kinugasa Y, Kato M, Sugihara S, Yanagihara K, Yamada K, Hirai M, Yamamoto K (2014) Multidisciplinary intensive education in the hospital improves outcomes for hospitalized heart failure patients in a Japanese rural setting. BMC Health Serv Res 14:351CrossRef
5.
go back to reference Umehara T, Katayama N, Tsunematsu M, Kakehashi M (2020) Factors affecting hospital readmission heart failure patients in Japan: a multicenter retrospective cohort study. Heart Vessels 35:367–375CrossRef Umehara T, Katayama N, Tsunematsu M, Kakehashi M (2020) Factors affecting hospital readmission heart failure patients in Japan: a multicenter retrospective cohort study. Heart Vessels 35:367–375CrossRef
6.
go back to reference Shiraishi Y, Kohsaka S, Sato N, Takano T, Kitai T, Yoshikawa T, Matsue Y (2018) 9-year trend in the management of acute heart failure in Japan: a report from the national consortium of acute heart failure registries. J Am Heart Assoc 7:e008687CrossRef Shiraishi Y, Kohsaka S, Sato N, Takano T, Kitai T, Yoshikawa T, Matsue Y (2018) 9-year trend in the management of acute heart failure in Japan: a report from the national consortium of acute heart failure registries. J Am Heart Assoc 7:e008687CrossRef
7.
go back to reference Mikami T, Ishii M, Yamamoto N, MarumeK NM, Ogata S, Kaichi R, Ikebe S, Mori T, Komaki S, Kusaka H, Toida R, Kurogi K, Iwanaga Y, Ogawa H, Miyamoto Y, Tsujita K (2021) Association of early administration of furosemide with improved oxygenation in patients with acute heart failure. ESC Heart Fail 8:3354–3359CrossRef Mikami T, Ishii M, Yamamoto N, MarumeK NM, Ogata S, Kaichi R, Ikebe S, Mori T, Komaki S, Kusaka H, Toida R, Kurogi K, Iwanaga Y, Ogawa H, Miyamoto Y, Tsujita K (2021) Association of early administration of furosemide with improved oxygenation in patients with acute heart failure. ESC Heart Fail 8:3354–3359CrossRef
8.
go back to reference Park JH, Balmain S, Berry C, Morton JJ, McMurray JJV (2010) Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart 96:533–538CrossRef Park JH, Balmain S, Berry C, Morton JJ, McMurray JJV (2010) Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart 96:533–538CrossRef
9.
go back to reference Kawase Y, Kadota K, Tada T, Hata R, Iwasaki K, Maruo T, Katoh H, Mitsudo K (2016) Predictors of worsening renal function in patients with acute decompensated heart failure treated by low-dose carperitide. Circ J 80:418–425CrossRef Kawase Y, Kadota K, Tada T, Hata R, Iwasaki K, Maruo T, Katoh H, Mitsudo K (2016) Predictors of worsening renal function in patients with acute decompensated heart failure treated by low-dose carperitide. Circ J 80:418–425CrossRef
10.
go back to reference Kawase Y, Hata R, Tada T, Katoh H, Kadota K (2018) Effects of carperitide on degree of pulmonary congestion in treatment of acute heart failure. Circ J 82:2079–2088CrossRef Kawase Y, Hata R, Tada T, Katoh H, Kadota K (2018) Effects of carperitide on degree of pulmonary congestion in treatment of acute heart failure. Circ J 82:2079–2088CrossRef
11.
go back to reference Matsuzaki M, Hori M, Izumi T, Fukunami M, Investigators T (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25:S33–S45CrossRef Matsuzaki M, Hori M, Izumi T, Fukunami M, Investigators T (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25:S33–S45CrossRef
12.
go back to reference Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, Shinagawa H, Ako J, Izumi T (2017) For the kanagawa aquaresis investigators effects of additive tolvaptan vs increased furosemide on heart failure with diuretic resistance and renal impairment—results from the K-STAR study. Circ J 82(159):167 Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, Shinagawa H, Ako J, Izumi T (2017) For the kanagawa aquaresis investigators effects of additive tolvaptan vs increased furosemide on heart failure with diuretic resistance and renal impairment—results from the K-STAR study. Circ J 82(159):167
13.
go back to reference Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N (2016) Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3:177–188CrossRef Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N (2016) Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3:177–188CrossRef
14.
go back to reference Nakao K, Horio T, Yoshimura R, Fujiwara R, Matsuoka Y, Yokouchi G, Nakamura H, Sakamoto Y, Fujimoto K, Izumiya Y, Yoshiyama M, Kasayuki N (2021) Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure. Heart Vessels 36:1175–1182CrossRef Nakao K, Horio T, Yoshimura R, Fujiwara R, Matsuoka Y, Yokouchi G, Nakamura H, Sakamoto Y, Fujimoto K, Izumiya Y, Yoshiyama M, Kasayuki N (2021) Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure. Heart Vessels 36:1175–1182CrossRef
15.
go back to reference Milo-Cotter O, Cotter G, Weatherley BD, Adams KF, Kaluski E, Uriel N, O’Connor CM, Felker GM (2008) Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. Eur J Heart Fail 10:196–200CrossRef Milo-Cotter O, Cotter G, Weatherley BD, Adams KF, Kaluski E, Uriel N, O’Connor CM, Felker GM (2008) Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. Eur J Heart Fail 10:196–200CrossRef
16.
go back to reference Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV (2003) Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290:2581–2587CrossRef Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV (2003) Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290:2581–2587CrossRef
17.
go back to reference Varat MA, Adolph RJ, Fowler NO (1972) Cardiovascular effects of anemia. Am Heart J 83:415–426CrossRef Varat MA, Adolph RJ, Fowler NO (1972) Cardiovascular effects of anemia. Am Heart J 83:415–426CrossRef
18.
go back to reference Groenveld HF, Januzzi JL, Damman K, Wijingaarden J, Hillege HL, Veldhuisen DJ, Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52:818–827CrossRef Groenveld HF, Januzzi JL, Damman K, Wijingaarden J, Hillege HL, Veldhuisen DJ, Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52:818–827CrossRef
19.
go back to reference Mentz RJ, Greene SJ, Ambrosy AP, Vaduganathan M, Subacius HP, Swedberg K, Maggioni AP, Nodari S, Ponikowski P, Anker SD, Butler J, Gheorghiade M (2014) Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the everest trial. Circ Heart Fail 7:401–408CrossRef Mentz RJ, Greene SJ, Ambrosy AP, Vaduganathan M, Subacius HP, Swedberg K, Maggioni AP, Nodari S, Ponikowski P, Anker SD, Butler J, Gheorghiade M (2014) Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the everest trial. Circ Heart Fail 7:401–408CrossRef
20.
go back to reference Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Kitakaze M, Kinugawa K, Kihara Y, Goto Y, Komuro I, Saiki Y, Saito Y, Sakata Y, Sato N, Sawa Y, Shiose A, Shimizu W, Shimokawa H, Seino Y, Node K, Higo T, Hirayama A, Makaya M, Masuyama T, Murohara T, Momomura S, Yano M, Yamazaki K, Yamamoto K, Yoshikawa T, Yoshimura M, Akiyama M, Anzai T, Ishihara S, Inomata T, Imamura T, Iwasaki Y, Ohtani T, Onishi K, Kasai T, Kato M, Kawai M, Kinugasa Y, Kinugawa S, Kuratani T, Kobayashi S, Sakata Y, Tanaka A, Toda K, Noda T, Nochioka K, Hatano M, Hidaka T, Fujino T, Makita S, Yamaguchi O, Ikeda U, Kimura T, Kohsaka S, Kosuge M, Yamagishi M, Yamashina A (2019) On behalf of the Japanese circulation society and the japanese heart failure society joint working group JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure—digest version. Circ J 83:2084–2184CrossRef Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Kitakaze M, Kinugawa K, Kihara Y, Goto Y, Komuro I, Saiki Y, Saito Y, Sakata Y, Sato N, Sawa Y, Shiose A, Shimizu W, Shimokawa H, Seino Y, Node K, Higo T, Hirayama A, Makaya M, Masuyama T, Murohara T, Momomura S, Yano M, Yamazaki K, Yamamoto K, Yoshikawa T, Yoshimura M, Akiyama M, Anzai T, Ishihara S, Inomata T, Imamura T, Iwasaki Y, Ohtani T, Onishi K, Kasai T, Kato M, Kawai M, Kinugasa Y, Kinugawa S, Kuratani T, Kobayashi S, Sakata Y, Tanaka A, Toda K, Noda T, Nochioka K, Hatano M, Hidaka T, Fujino T, Makita S, Yamaguchi O, Ikeda U, Kimura T, Kohsaka S, Kosuge M, Yamagishi M, Yamashina A (2019) On behalf of the Japanese circulation society and the japanese heart failure society joint working group JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure—digest version. Circ J 83:2084–2184CrossRef
21.
go back to reference Ponikowski P, Vorrs AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Meer P (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37(2129):2200 Ponikowski P, Vorrs AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Meer P (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37(2129):2200
22.
go back to reference Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL (2013) American college of cardiology foundation; american heart association task force on practice guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 62:e147–e239CrossRef Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL (2013) American college of cardiology foundation; american heart association task force on practice guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 62:e147–e239CrossRef
23.
go back to reference Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america. J Am Coll Cardiol 70:776–803CrossRef Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america. J Am Coll Cardiol 70:776–803CrossRef
24.
go back to reference McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) PARADIGM-HF investigators committees, angiotensin-neprilysin inhibition versus enarapril in heart failure. N Engl J Med 371(993):1004 McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) PARADIGM-HF investigators committees, angiotensin-neprilysin inhibition versus enarapril in heart failure. N Engl J Med 371(993):1004
25.
go back to reference McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, Meara EO, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM (2019) DAPA-HF Trial committees investigators, dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(1995):2008 McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, Meara EO, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM (2019) DAPA-HF Trial committees investigators, dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(1995):2008
26.
go back to reference Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators SHIFT (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 376:875–885CrossRef Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators SHIFT (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 376:875–885CrossRef
27.
go back to reference Nakane E, Kato T, Tanaka N, Kuriyama T, Kimura K, Nishiwaki S, Hamaguchi T, Morita Y, Yamaji Y, Haruna Y, Haruna T, Inoko M (2021) Association of the induction of a self-care management system with 1-year outcomes in patients hospitalized for heart failure. J Cardiol 77:48–56CrossRef Nakane E, Kato T, Tanaka N, Kuriyama T, Kimura K, Nishiwaki S, Hamaguchi T, Morita Y, Yamaji Y, Haruna Y, Haruna T, Inoko M (2021) Association of the induction of a self-care management system with 1-year outcomes in patients hospitalized for heart failure. J Cardiol 77:48–56CrossRef
28.
go back to reference Kinugasa Y, Saitoh M, Ikegame T, Ikarashi A, Kadota K, Kamiya K, Kohsaka S, Mizuno A, Miyajima I, Nakane E, Nei A, Shibata T, Yokoyama H, Yumikura S, Yumino D, Watanabe N, Isobe M (2021) Research team for the provision of heart failure care centered on general practitioners in the community differences in priorities for heart failure management between cardiologist and general practitioners in Japan. Circ J 85(1565):1574 Kinugasa Y, Saitoh M, Ikegame T, Ikarashi A, Kadota K, Kamiya K, Kohsaka S, Mizuno A, Miyajima I, Nakane E, Nei A, Shibata T, Yokoyama H, Yumikura S, Yumino D, Watanabe N, Isobe M (2021) Research team for the provision of heart failure care centered on general practitioners in the community differences in priorities for heart failure management between cardiologist and general practitioners in Japan. Circ J 85(1565):1574
29.
go back to reference Tsuchihashi-Makaya M, Matsuo H, Kakinoki S, Takechi S, Kinugawa S, Tsutsui H (2013) J-HOMECARE Investigators home-based disease management program to improve psychological status in patients with heart failure in Japan. Circ J 77(926):933 Tsuchihashi-Makaya M, Matsuo H, Kakinoki S, Takechi S, Kinugawa S, Tsutsui H (2013) J-HOMECARE Investigators home-based disease management program to improve psychological status in patients with heart failure in Japan. Circ J 77(926):933
Metadata
Title
Trends in prognosis after hospitalization for acute heart failure in Kurashiki Central hospital 2015–2018: single-center prospective study
Authors
Yuichi Kawase
Kenta Yoshida
Shunsuke Matsushita
Takeshi Tada
Hiromi Yamamoto
Harumi Katoh
Kazushige Kadota
Publication date
24-06-2022
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 12/2022
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-022-02116-w

Other articles of this Issue 12/2022

Heart and Vessels 12/2022 Go to the issue